Pathoquest_logo
  • About Us
    • Why PathoQuest
    • Leadership Team
    • Strategic Partnerships
    • Client Testimonials
    • Careers
  • Modalities
    • mAbs and Recombinant Proteins
    • Viral Vectors
    • Cell Therapies
    • Vaccines
    • RNA Therapies
    • Cultivated Meat
  • Services
    • Adventitious Virus Testing
    • In Vivo Replacement
    • Cell Line Characterization
    • Identity Confirmation
    • HLA Genotyping
    • Integration Site Analysis
    • Raw Material Testing
  • iDTECT® Platform
  • 3Rs
  • Quality & Regulatory
    • Quality
    • Regulatory
  • Resources
    • Publications
    • Brochures and Posters
    • Webinars and Talks
    • Our One-Minute Series on NGS
  • News
  • Contact

Webinar – FEB 8, 2024 | Applications of Next Generation Sequencing for Viral Safety in Light of ICH Q5A R2 (Joint Webinar with Bristol Myers Squibb)

by Delphine Gricourt | Dec 28, 2023 | News

CLICK HERE TO BOOK YOUR FREE SEAT JOINT WEBINAR Bristol Myers Squibb & PathoQuest  Applications of Next Generation Sequencing for Viral Safety in Light of ICH Q5A R2 08th February 2024 10:00am EST / 7:00am PST / 3:00pm GMT / 4:00pm CET Presented by: Jurgen...

Revised ICHQ5A(R2) is adopted: call for action in viral safety testing!

by Delphine Gricourt | Nov 22, 2023 | News

The updated ICHQ5A(R2) guideline adopted in November 2023 highlights the benefits of Next Generation Sequencing assays versus in vivo assays: 3.2.3: “NGS is encouraged as a replacement for in vivo assays because it can overcome the limitations of the breadth and...

Webinar Replay – Integration Site Analysis: An innovative method for faster, more certain clone selection & genetic stability testing

by Larry Yost | Oct 23, 2023 | News

CLICK HERE TO LISTEN TO THE WEBINAR REPLAY Listen to an archived version of our recent webinar which provided information on our new integration site analysis assay. The assay uses Cas9 targeted DNA cleavage combined with nanopore sequencing technology to...

Substitution of in vitro and in vivo virus testing with PathoQuest NGS confirmed by French Agency.

by Larry Yost | Sep 14, 2023 | News

Substitution of in vitro and in vivo virus testing with PathoQuest NGS confirmed by French Agency PathoQuest is pleased to announce that the Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM) have recently published their review of PathoQuest’s...

PathoQuest Announces Head-to-Head Study Validating Proprietary Next Generation Sequencing Viral Safety Assay as a Reliable In Vitro Alternative to Animal Testing Methods

by Larry Yost | Sep 6, 2023 | News, Press Release

PathoQuest Announces Publication of a Head-to-Head Study Validating Proprietary NGS Viral Safety Assay as a Reliable Alternative to Animal Testing   NGS assay demonstrated a broader detection range than standard in vivo tests with comparable or higher analytical...

PathoQuest now offering GMP validated NGS Viral Vector Identity test at U.S. site

by Larry Yost | Aug 21, 2023 | News

PathoQuest now offering GMP validated NGS Viral Vector Identity test at U.S. site We now offer our GMP validated Viral Vector Identity test at our Wayne, PA site, as well as at our site in Paris, France. Our NGS-based identity test is performed on a short read...
« Older Entries
Next Entries »

Home » News » Page 3

T: +33 (0)1 70 82 17 90
T: +1 484 212 9360

Copyright © 2024 – PathoQuest | Cookies Policy | Privacy Policy

× NGS One Minute Series

T: +33 (0)1 70 82 17 90
T: +1 484 212 9360

Copyright © 2023 – PathoQuest | Cookies Policy | Privacy Policy

Cleantalk Pixel
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}

Analytical Methods Validation Head contact form

Name(Required)
Max. file size: 50 MB.
Max. file size: 50 MB.